Astrazeneca Plc ADR (AZN)

Feb 20, 2025, 3:56 PM EST - 2 days ago

Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN

Feb 20, 2025, 3:00 PM EST - 2 days ago

AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline

Feb 20, 2025, 1:25 PM EST - 2 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN

Feb 20, 2025, 1:08 PM EST - 2 days ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

FGEN

Feb 20, 2025, 6:40 AM EST - 2 days ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

FGEN

Feb 19, 2025, 1:00 PM EST - 3 days ago

AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold

Feb 19, 2025, 11:23 AM EST - 3 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

Feb 16, 2025, 9:24 AM EST - 6 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

Feb 14, 2025, 12:32 PM EST - 8 days ago

AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman

Feb 12, 2025, 4:00 AM EST - 10 days ago

New Interactive Storybook Aims to Educate Children with Rare Kidney Disease into a World of Adventure and Understanding

Feb 11, 2025, 1:42 PM EST - 11 days ago

AstraZeneca (AZN) Reels from China Investigation and Investor Suit - Hagens Berman

Feb 11, 2025, 1:29 PM EST - 11 days ago

Final Trades: Trade Desk, Leidos Holdings, Astrazeneca and Devon Energy

DVN LDOS TTD

Feb 6, 2025, 12:16 PM EST - 16 days ago

AstraZeneca PLC (AZN) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 8:40 AM EST - 16 days ago

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China

Feb 6, 2025, 7:00 AM EST - 16 days ago

AstraZeneca's Full Year and Q4 2024 results

Feb 6, 2025, 2:10 AM EST - 16 days ago

AstraZeneca 2025 sales outlook tops expectations

Feb 5, 2025, 1:05 AM EST - 17 days ago

AstraZeneca shareholders say they need clarity on China investigations

Feb 3, 2025, 12:05 PM EST - 19 days ago

UK hits back at AstraZeneca over collapse of investment deal

Jan 31, 2025, 9:15 AM EST - 22 days ago

AstraZeneca ditches plan to build $558 mln UK vaccine plant

Jan 31, 2025, 8:00 AM EST - 22 days ago

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Jan 30, 2025, 11:00 PM EST - 22 days ago

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

Jan 29, 2025, 9:49 AM EST - 24 days ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

Jan 27, 2025, 6:00 PM EST - 26 days ago

ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

Jan 27, 2025, 6:00 PM EST - 26 days ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Jan 27, 2025, 5:45 AM EST - 26 days ago

Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN